BioWorld

Oct. 18, 2004

CoTherix Prices IPO Low, Raises $30M For Ventavis

MacroGenics Raises $30M In Second-Round Financing

ViRexx Enters Agreement To Buy Familiar Firm: AltaRex

Other News To Note

Appointments And Advancements

La Jolla's Riquent Approvable Letter: Finished Study Needed

La Jolla Pharmaceutical Co. received an approvable letter for its lupus drug candidate Riquent that requires the completion of another clinical study for final approval. (BioWorld Today) Read More

Hardy Attempt' At H&Q-Style Meeting Wins Attendee Praise

Today's news in brief

BioWorld

BioWorld briefs for June 15, 2026.

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...

Microbiota modulates the antidepressant effects of GLP-1 analogues

BioWorld Science

Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...

Microscopic image of chronic myeloid leukemia

Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid

BioWorld

Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...

EHA 2026: With new lenses, a changing view on pediatric cancers

BioWorld

In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...